Luca Incrocci

Luca Incrocci is Professor and Head of Genitourinary Oncology in the Department of Radiation Oncology at Erasmus MC Cancer Institute in Rotterdam, the Netherlands. He is one of Europe's foremost experts in brachytherapy for prostate cancer and a leading international authority on sexual function and quality-of-life outcomes following radiotherapy. Over more than two decades, Incrocci has built a comprehensive clinical and research program at Erasmus MC focused on optimizing both oncological control and patient-reported functional outcomes in men treated with external beam radiotherapy, low-dose-rate (LDR) brachytherapy seed implantation, and high-dose-rate (HDR) brachytherapy boost combinations. Incrocci's most impactful contribution is his meticulous long-term follow-up of prostate cancer patients with respect to erectile dysfunction, urinary incontinence, and bowel toxicity—outcomes that profoundly affect quality of life but were systematically underreported in early trials. He has led randomized trials comparing dose-escalated EBRT with LDR brachytherapy boost in intermediate- and high-risk prostate cancer, and has contributed to phase III trials evaluating hypofractionation schedules and their differential impact on urinary and sexual function. His work has established that the choice between treatment modalities must incorporate careful patient counseling about long-term sexual health effects. Incrocci has served on multiple European Society for Radiotherapy and Oncology (ESTRO) and European Association of Urology (EAU) guideline panels, contributing to consensus documents on prostate cancer radiotherapy, brachytherapy quality assurance, and sexual dysfunction management. He is a prolific author in journals including the Journal of Clinical Oncology, European Urology, Radiotherapy and Oncology, and the International Journal of Radiation Oncology Biology Physics. His teaching and training activities have influenced radiotherapy practice across Europe, and he has trained numerous Dutch and international radiation oncologists specializing in genitourinary tumors.